Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auto-CD34+ cells for refractory angina
NCT01508910Phase 3Completed
- Sponsor
- Lisata Therapeutics
- Start
- Apr 2012
- Primary completion
- Nov 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of autologous CD34+ cells in angina pectoris, chronic myocardial ischemia (CMI), sponsored by Lisata Therapeutics. Started Apr 2012; status: completed.
02
Drugs
autologous CD34+ cells
03
Conditions
angina pectorischronic myocardial ischemia (CMI)
Beyond the preview
Go deeper on NCT01508910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01508910.